open access publication

Article, 2024

Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study

Influenza and Other Respiratory Viruses, ISSN 1750-2659, 1750-2640, Volume 18, 4, Page e13292, 10.1111/irv.13292

Contributors

Monge, Susana 0000-0003-1412-3012 (Corresponding author) [1] [2] Humphreys, James 0009-0004-3789-8309 [3] Nicolay, Nathalie [4] Braeye, Toon 0000-0002-5637-4613 [5] Van Evercooren, Izaak [5] Hansen, Christian Holm 0000-0002-5949-0097 [6] Emborg, Hanne-Dorthe 0000-0001-8062-0864 [6] Sacco, Chiara 0000-0002-3958-8353 [4] [7] Mateo-Urdiales, Alberto 0000-0002-0480-8723 [7] Castilla, Jesús 0000-0002-6396-7265 [8] [9] Martínez-Baz, Iván 0000-0002-3405-2277 [8] [9] De Gier, Brechje [10] Hahné, Susan J M [10] Meijerink, Hinta 0000-0002-5898-2778 [11] Kristoffersen, Anja Bråthen [11] Machado, Ausenda Cristina Nelson 0000-0002-1849-1499 [12] Soares, Patrícia 0000-0001-5033-9115 [12] Nardone, Anthony 0000-0003-1138-0937 [3] Bacci, Sabrina [4] Kissling, Esther [3] Nunes, Baltazar 0000-0001-6230-7209 [3] Group, VEBIS‐EHR Working

Affiliations

  1. [1] Centro de Investigación Biomédica en Red
    2. [NORA names: Spain; Europe, EU; OECD];
  2. [2] Instituto de Salud Carlos III
    3. [NORA names: Spain; Europe, EU; OECD];
  3. [3] Epiconcept, Paris, France
    4. [NORA names: Miscellaneous; France; Europe, EU; OECD];
  4. [4] European Centre for Disease Prevention and Control
    5. [NORA names: Sweden; Europe, EU; Nordic; OECD];
  5. [5] Sciensano (Belgium)
    6. [NORA names: Belgium; Europe, EU; OECD];

Abstract

Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.

Keywords

Adjusted hazard ratios, COVID-19, COVID-19 hospitalisation, COVID-19 vaccine, Cox, Cox model, EU/EEA, EU/EEA countries, Economic Area, European Union/European Economic Area, XBB, area, benefits, cohort, countries, death, dominance, effect, estimate adjusted hazard ratios, hazard ratio, hospitalisation, individuals, model, network studies, period, periodic vaccination, protocol, ratio, results, retrospective cohort, strategies, study, vaccination of individuals, vaccination strategies, vaccine, vaccine effectiveness, years

Funders

  • European Centre for Disease Prevention and Control
  • Fundação para a Ciência e Tecnologia

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+